As part of our ongoing commitment to exploring unmet need across the spectrum of atherothrombotic disease, including stroke, AstraZeneca is pleased to support a new report from The Economist Intelligence Unit (EIU). The report, Addressing the global stroke burden, explores the impact of stroke on societies around the world, highlighting its increasingly heavy socioeconomic burden, especially in low- and middle-income countries.
Stroke is the second most common cause of death in low- and middle-income countries and the third most common in higher-income countries. It is also a major cause of adult disability and, with an ageing population, the prevalence of stroke is rising in high-income countries. To help address this burden, AstraZeneca is committed to supporting research that helps to understand what needs to be done to help meet global stroke-reduction targets.